tbuckley/cabot-search huggingface dataset:
Osler–Weber–Rendu Syndrome
Authors: Luis M Pérez-Belmonte, Elisabeth Gomez-Moyano
Journal: New England Journal of Medicine (2015)

A 58-year-old woman presented with intermittent passage of bright red blood from the rectum, progressive fatigue, and dyspnea. Examination revealed telangiectasias on the labial mucosa and nail folds. Her mother was reported to have frequent epistaxis and similar skin lesions.
P2-19-03: Influence of Zoledronic Acid on BMD in Premenopausal Women with Breast Cancer and Neoadjuvant or Adjuvant Chemotherapy and/or Endocrine Treatment – The ProBone Studies.
Authors: P Hadji, A Kauka, T Bauer, M Kalder, U Albert, K Birkholz, M Baier, M Muth, M Ziller
Journal: Cancer Research (2011)

Abstract Background: Based on baseline bone mineral density (BMD), adjuvant chemotherapy or endocrine therapy for early breast cancer patients can lead to substantially increased fracture risk. A significant decrease of BMD &amp;gt;10% after 2 years of chemotherapy (CT) and/or endocrine therapy (ET) has been reported. In recent studies, zoledronic acid (ZOL) produced an increase in BMD in premenopausal and postmenopausal patients with breast cancer (ABCSG-12, Z-FAST, ZO-FAST, etc). In addition, a significant increase in disease-free survival (DFS) with ZOL vs no ZOL was observed in most of these studies. Methods: The aim of 2 single-center, placebo-controlled, randomized studies—Probone I and Probone II—was to investigate the effect of adjuvant treatment with ZOL on BMD in premenopausal women with early breast cancer treated with CT and/or ET. Patients with hormone-receptor-negative (HR−) breast cancer (Probone I) were treated with (neo)adjuvant CT; patients with hormone-receptor-positive (HR+) breast cancer (Probone II) were treated with ET alone or in combination with (neo)adjuvant CT. Randomized patients received ZOL 4 mg or placebo IV every 3 months for 24 months. The primary objective was the change in BMD at the lumbar spine between baseline and month 24 (measured by dual-energy X-ray absorptiometry [DXA]). Secondary objectives included DFS; BMD at total hip, femur, and os calcis; quantitative ultrasonometry (QUS) at os calcis and phalanges; markers of bone turnover (C-telopeptide of type I collagen [CTX] and N-terminal propeptide of type I procollagen [P1NP]); endocrine hormones (follicle-stimulating hormone [FSH], estradiol, testosterone, sex hormone-binding globulin [SHBG], parathyroid hormone [PTH], vitamin D, anti-Müllerian hormone [AMH], inhibin A/B, etc); pathologic fractures; and safety and tolerability. Results: 70 HR+ and 11 HR− breast cancer patients have been enrolled into the studies. The last patient will have been treated for 24 months by the end of June 2011. Conclusions: The effects of ZOL on lumbar spine BMD at 24 months and secondary endpoints will be presented at the meeting. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P2-19-03.
Abstract 1154: Direct detection of DNA methylation and mutagenic damage through single-molecule, real-time (SMRTTM) DNA sequencing
Authors: Benjamin Flusberg, Dale Webster, Kevin Travers, Eric Olivares, Jonas Korlach, Stephen Turner
Journal: Cancer Research (2010)

Abstract Changes in genomic methylation patterns are often associated with cancer processes. The development of new, high-throughput techniques for mapping aberrant methylation patterns, along with various forms of DNA damage, will be important for advancing cancer research. Single-molecule real-time (SMRTTM) sequencing yields a rich set of information about nucleic acid structure that allows direct detection of various forms of modified nucleotides, including 5-methylcytosine, 5-hydroxymethylcytosine, N6-methyladenosine, and 8-oxoguanosine. We have studied DNA templates with a range of CpG methylation patterns, and we describe how this approach, in combination with circular consensus sequencing of individual DNA molecules, can be used for base-pair resolution identification of epigenetic modifications. Unlike current bisulfite-sequencing techniques, which are limited by short read lengths and by the reduction in genomic complexity, our method will enable mapping of methylation patterns within even highly repetitive genomic regions. Overall, these results highlight the potential applications of the SMRTTM technology to high-throughput sequencing of methylation and mutagenic DNA lesions. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1154.
OP0071 Efficacy and safety of diclofenac diethylamine 1.16% gel in the treatment of acute neck pain: A randomized, double-blind, placebo-controlled study
Authors: H.G. Predel, B. Giannetti, I. Burnett, A.M. Hug
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Neck pain (NP) is a common musculoskeletal disorder that affects up to 71% of the population at some point in their lifetime<sup>1</sup> and is a frequent cause of discomfort. Characteristics include neck pain, often accompanied by some of the classical symptoms of inflammation. Non-steroidal anti-inflammatory drugs (NSAIDs) are used to reduce neck pain and inflammation, and thus facilitate earlier recovery and rehabilitation. Topical diclofenac diethylamine (DDEA) 1.16% gel is an NSAID that has been clinically proven to be effective and well tolerated in the management of acute and chronic musculoskeletal conditions.<sup>2</sup> Until now, however, no clinical data were available to support its use in the treatment of NP. <h3>Objectives</h3> To assess the efficacy and safety of DDEA 1.16% gel in the treatment of acute NP under "in-use" conditions. <h3>Methods</h3> In a randomized, double-blind, placebo-controlled, multi-center, parallel group study, patients with NP originating from cervical joints and accompanying soft tissues (n=72; mean age 33.8 years) were randomized to treatment with DDEA 1.16% gel (2 g, 4x/day, for 5 days) or placebo. Efficacy assessments included pain-on-movement (POM; primary efficacy variable), pain-at-rest (PAR), functional neck disability index (NDI), global assessment of treatment and response to treatment (decrease in POM by 50% after 48 h). Adverse events (AEs) were recorded at every visit. <h3>Results</h3> The primary outcome, POM at 48 hours, was almost three times lower with DDEA 1.16% gel compared with placebo (19.5 mm vs. 56.9 mm; p&lt;0.0001); this corresponded to a clinically-relevant 75% change from baseline with DDEA 1.16% gel compared with 23% with placebo. With DDEA 1.16% gel, all POM scores from the first assessment at 1 h through to 96 h were significantly lower than with placebo (p&lt;0.0001). PAR and NDI scores (first assessment at 24 h) were also significantly lower with DDEA 1.16% gel when compared with placebo (p&lt;0.0001). By Day 5, 100% of DDEA 1.16% gel patients rated treatment as "good" to "excellent" compared with just 19.4% of placebo patients (p&lt;0.0001). Overall, 94.4% of DDEA 1.16% gel patients responded to treatment compared with 8.3% of placebo patients (p&lt;0.001). Only one AE was observed (headache in the placebo group). <h3>Conclusions</h3> This study demonstrated that DDEA 1.16% gel is effective in rapidly reducing neck pain and restoring neck function and is well tolerated. <h3>References</h3> [1]Fejer R, Kyvik K, Hartvigsen J. Eur Spine J 2006; 15(6):834-848. [2]Zacher J, Altman R, Bellamy N et al. Curr Med Res Opinion 2008; 24(4):925-950. <h3>Disclosure of Interest</h3> H. Predel Grant/Research support from: Research support received from Novartis, B. Giannetti: None Declared, I. Burnett Employee of: Novartis Consumer Health, A. Hug Employee of: Novartis Consumer Health
AB0858-PARE “Ageing healthy”-obtain know-how to live and age healthy
Authors: S. David
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Upon the completion of a therapeutic work with a client, the person develops new habits and traits, thus distances stress, anxiety, "buts, don'ts, and no's" from his life and displays "healthier" behaviors in all aspects. If this accomplishment is important for every person, for an RMD patient it's a must, it's a necessity. As stressful situations "damage" the person, similarly Rumatoid arthritis, finds space to grow within the person. <h3>Objectives</h3> Patients with RMD, need to learn to live and deal with pain, so as to acquire a balanced present life and secure making friend of time. Ageing healthy, prerequisites, living healthy. Having the know-how, to employ health habits from exercising, to good nutrition and to a positive way of thinking, it's a task that could be "taught and learned." Through my work, my duty is to teach an RMD patient, how to live within the "Healthy Triangle". The Rheumatoid patient should be taught to undertake the responsibility of taking care of his body and spirit. Medical advisory, exercise, healthy nutrition habits are on the one end of the triangle, positive way of thinking and sentimental stability stand on the other end, and all point to the top of the pyramid, being healthy along the life span of the person. <h3>Methods</h3> The person is guided into taking actions one completing the other within the pyramid of Health. Weekly exercise programs, healthy eating and cooking habits, having low fat and still delicious meals. Any kind of social, pleasant activities, which reduce stress and enhance creativity, as painting, drawing, acting, music. Definitely, the person should join in a therapeutic group or private therapy, so as to balance the distressful feelings over the disease with reality. <h3>Results</h3> Living today, having a balanced day-to-day schedule, will result for the person, when entering the "Health Triangle". Have inner peace, enjoy moments, outings with friends, time alone, grasp the moment. The key is to learn to display such new habits. Employing, a new set of behaviors, will point all days valuable, present and future. <h3>Conclusions</h3> Rheumatoid disease demanded some role in the "Theatrical Play" of your life. You are in control, you are the director. Choose to grand the disease a minor role. Appoint her as the stage boy, who has no lines to speak out, but silently does his errants. Likewise, once the disease is set under limits, it will be present silently, while the "Play" will successfully go on, to the end of your days. <h3>References</h3> Private practice, Group therapy, Workshops at the Cyprus League against Rheumatism <h3>Disclosure of Interest</h3> None Declared
Abstract 529: Matrix metalloproteinase expression and secretion in papillary thyroid carcinoma
Authors: Nicolas T. Kummer, Josh Bedwell, Theodore S. Nowiki, Stimson Schantz, Edward Shin, Steven Schaefer, Raj K. Tiwari, Jan Geliebter
Journal: Cancer Research (2010)

Abstract In the last decade, the incidence of thyroid cancer has risen ∼84% and mortality ∼34%. The ACS estimates ∼ 37,200 new cases of thyroid cancer, with 1,630 deaths in 2009. Papillary thyroid carcinoma (PTC) is the most common thyroid and endocrine malignancy, accounting for ∼80% of all thyroid cancer. It typically occurs from a gain-of-function mutation in the RET, RAS or BRAF genes which make up a linear signaling cascade for ERK activation. Recurrent or persistent disease prevails in up to 40% of thyroidectomy cases with a poor prognosis when aggressive cancer is evident. Thus, further research into factors contributing to aggressive disease is merited. Matrix metalloproteinases (MMPs) represent a family of secreted proteases with diverse functions implicated in the pathogeneses of aggressive tumors. Their functions include degrading the extracellular matrix (ECM) to facilitate cell migration, cell signaling through ECM cleavage products that can affect apoptosis and cell growth, and they can act directly on growth factor precursors and receptors. MMP upregulation has been demonstrated in many types of cancers yet its pattern of expression is poorly understood in PTC. Analysis of MMPs and tissue inhibitors of metalloproteinases (TIMPs) in the human PTC cell line, BCPAP, and the normal thyroid cell line, NTHY-ori by protein array and real-time RT-PCR revealed significantly elevated levels of MMPs and decreased levels of TIMP-4. Real time RT-PCR demonstrated the following fold increases in expression in BCPAP compared to NTHY-ori: 16. 9 (SE=0.79) for MMP-1, 1.80 (SE=0.41) for MMP-3, 1.40 (SE=0.08) for MMP-9, 7.12 (SE=2.14) for MMP-10, 12.60 (SE=6.90) for MMP-13 and increased levels of TIMP-4 in NTHY-ori compared to BCPAP of 2.38 (SE=1.04). Protein array data from serum free conditioned media of the cell lines reflected a similar pattern of secreted MMP and TIM4 levels. Fold increases in the optical concentration (determined by spot densitometry) of secreted proteins were detected in BCPAP compared to NTHY-ori of 29.48 (SE=1.92) for MMP-1, 16.80 (SE=1.07) for MMP-3, 1.66 (SE=0.07) for MMP-9, 3.66 (SE=0.55) for MMP-10, 1.59 (SE=0.11) for MMP-13 and increased levels of TIMP-4 in NTHY-ori compared to BCPAP of 1.27 (SE=0.06). For the first time, these results demonstrate increased production and secretion of a group of MMPs and down regulation of TIMP-4 which have been characterized in tumor progression in a PTC cell line. Further investigation into the role these agents play in the tumorgenesis of aggressive PTC may yield insight into future treatment and screening alternatives. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 529.
IMPACT OF A PHYSICIAN-GUIDED VERSUS STANDARD MINIMUM 24 HOUR CORONARY CARE UNIT STAY ON OUTCOMES IN STABLE PATIENTS WHO HAVE RECEIVED PRIMARY PERCUTANEOUS CORONARY INTERVENTION FOR ST-ELEVATION MYOCARDIAL INFARCTION
Authors: William F. McIntyre, Shuangbo Liu, Brett M. Hiebert, Philip Garber
Journal: Journal of the American College of Cardiology (2016)
Patients With Psoriasis and Personalized Trade-offs in Treatment Decisions—Lessons Learned From Focus Groups
Authors: Jaehwan Kim, Dong Joo Kim, Francesca S. Ortenzio, Lynn Dare, Christine Frank, Rhonda G. Kost, Michelle A. Lowes
Journal: JAMA Dermatology (2016)

This assessment of the treatment decision-making experiences of patients with psoriasis identifies patient preferences that can be incorporated into a subsequent design of decision aids for individuals with psoriasis.
International linkage of two food-borne hepatitis A clusters through traceback of mussels, the Netherlands, 2012
Authors: Ingeborg L.A. Boxman, Linda Verhoef, Harry Vennema, Siew-Lin Ngui, Ingrid H.M. Friesema, Chris Whiteside, David Lees, Marion Koopmans
Journal: Eurosurveillance (2016)

This report describes an outbreak investigation starting with two closely related suspected food-borne clusters of Dutch hepatitis A cases, nine primary cases in total, with an unknown source in the Netherlands. The hepatitis A virus (HAV) genotype IA sequences of both clusters were highly similar (459/460 nt) and were not reported earlier. Food questionnaires and a case–control study revealed an association with consumption of mussels. Analysis of mussel supply chains identified the most likely production area. International enquiries led to identification of a cluster of patients near this production area with identical HAV sequences with onsets predating the first Dutch cluster of cases. The most likely source for this cluster was a case who returned from an endemic area in Central America, and a subsequent household cluster from which treated domestic sewage was discharged into the suspected mussel production area. Notably, mussels from this area were also consumed by a separate case in the United Kingdom sharing an identical strain with the second Dutch cluster. In conclusion, a small number of patients in a non-endemic area led to geographically dispersed hepatitis A outbreaks with food as vehicle. This link would have gone unnoticed without sequence analyses and international collaboration.
AB0033 Intracellular Expression of Survivin and Bcl-6 is Decreased in CD4+ T-Cells of Rheumatoid Arthritis Patients with High Serum Survivin
Authors: M. Turkkila, N. Filluelo Cavallini, S. Töyrä Silfverswärd, M. Erlandsson, M. Brisslert, R. Pullerits, K. Andersson, M. Bokarewa
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Survivin is recognized as a marker of persistently active and erosive RA. The findings in experimental arthritis suggested that survivin co-ordinates the antigen-dependent leukocyte maturation and function by regulating transcriptional activity of Bcl-6, essential factor of germinal center formation and a factor involved neoplastic transformation to lymphoma. <h3>Objectives</h3> We studied intracellular expression of survivin and Bcl-6 in the peripheral lymphocytes and its relation to clinical features and treatment of RA patients. <h3>Methods</h3> The intracellular expression of survivin and Bcl-6 was studied on the effector and memory subsets of CD4+ and CD8+ T-cells and in CD19+ B-cells in 18 RA patients using flow cytometry. Serum and mRNA levels of survivin were analysed in 144 RA patients (age 21-71 years, disease duration 1-49 years) using ELISA and qPCR, respectively. Patients with serum levels of survivin &gt;0.45 ng/mL comprised the serum survivin-positive (sSurv+) group. <h3>Results</h3> The sSurv+ group (n=76) was characterized by higher frequency of RF+ and aCCP+ patients, as well as by higher levels of aCCP and of differentiation factor Flt3-ligand compared to sSurv<sup>–</sup> (n=68). The sSurv+ and sSurv- patients were similar with respect to age, disease duration, DAS28 and anti-rheumatic treatment. Intracellular mRNA levels of Bcl-6 were lower in sSurv<sup>+</sup> compared to sSurv<sup>–</sup> patients, while RNA of survivin were similar. Flow cytometry showed that survivin was present in &gt;85% of non-stimulated T-cells and B-cells lymphocytes of RA patients. The survivin<sup>hi</sup> subset comprised 2-14% of T-cells and was enriched in the effector (CD62L<sup>neg</sup>) population of CD4+ T-cells compared to central memory and naïve CD4+ T-cells. The expression of Bcl-6 was found within 7-38% of survivin<sup>+</sup> effector CD4+ T-cells and in 21-69% of CD19+ B-cells. The subsets of survivin+ and of survivin+Bcl-6+ T-cells was smaller in the sSurv+ patients compared to sSurv<sup>–</sup> patients, and was inversely correlated to the levels of serum survivin in these patients. The subset of survivin+Bcl-6+ B-cells was similar in sSurv+ and sSurv- patients. <h3>Conclusions</h3> In this pilot study we demonstrate that RA patients have co-expression of the two oncoproteins involved in neoplastic transformation to lymphoma, survivin and Bcl-6. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.5490
HPV Involvement in Head and Neck Cancers: Comprehensive Assessment of Biomarkers in 3680 Patients
Authors: Xavier Castellsagué, Laia Alemany, Miquel Quer, Gordana Halec, Beatriz Quirós, Sara Tous, Omar Clavero, Llúcia Alòs, Thorsten Biegner, Tomasz Szafarowski, Maria Alejo, Dana Holzinger, Enrique Cadena, Edith Claros, Gillian Hall, Jan Laco, Mario Poljak, Maria Benevolo, Elena Kasamatsu, Hisham Mehanna, Cathy Ndiaye, Núria Guimerà, Belen Lloveras, Xavier León, Juan C. Ruiz-Cabezas, Isabel Alvarado-Cabrero, Chang-Suk Kang, Jin-Kyoung Oh, Marcial Garcia-Rojo, Ermina Iljazovic, Oluseyi F. Ajayi, Flora Duarte, Ashrafun Nessa, Leopoldo Tinoco, Marco A. Duran-Padilla, Edyta C. Pirog, Halina Viarheichyk, Hesler Morales, Valérie Costes, Ana Félix, Maria Julieta V. Germar, Marisa Mena, Arzu Ruacan, Asha Jain, Ravi Mehrotra, Marc T. Goodman, Luis Estuardo Lombardi, Annabelle Ferrera, Sani Malami, Estela I. Albanesi, Pablo Dabed, Carla Molina, Rubén López-Revilla, Václav Mandys, Manuel E. González, Julio Velasco, Ignacio G. Bravo, Wim Quint, Michael Pawlita, Nubia Muñoz, Silvia de Sanjosé, F. Xavier Bosch
Journal: JNCI Journal of the National Cancer Institute (2016)

We conducted a large international study to estimate fractions of head and neck cancers (HNCs) attributable to human papillomavirus (HPV-AFs) using six HPV-related biomarkers of viral detection, transcription, and cellular transformation. Formalin-fixed, paraffin-embedded cancer tissues of the oral cavity (OC), pharynx, and larynx were collected from pathology archives in 29 countries. All samples were subject to histopathological evaluation, DNA quality control, and HPV-DNA detection. Samples containing HPV-DNA were further subject to HPV E6*I mRNA detection and to p16INK4a, pRb, p53, and Cyclin D1 immunohistochemistry. Final estimates of HPV-AFs were based on HPV-DNA, HPV E6*I mRNA, and/or p16INK4a results. A total of 3680 samples yielded valid results: 1374 pharyngeal, 1264 OC, and 1042 laryngeal cancers. HPV-AF estimates based on positivity for HPV-DNA, and for either HPV E6*I mRNA or p16INK4a, were 22.4%, 4.4%, and 3.5% for cancers of the oropharynx, OC, and larynx, respectively, and 18.5%, 3.0%, and 1.5% when requiring simultaneous positivity for all three markers. HPV16 was largely the most common type. Estimates of HPV-AF in the oropharynx were highest in South America, Central and Eastern Europe, and Northern Europe, and lowest in Southern Europe. Women showed higher HPV-AFs than men for cancers of the oropharynx in Europe and for the larynx in Central-South America. HPV contribution to HNCs is substantial but highly heterogeneous by cancer site, region, and sex. This study, the largest exploring HPV attribution in HNCs, confirms the important role of HPVs in oropharyngeal cancer and drastically downplays the previously reported involvement of HPVs in the other HNCs.
Visualization of Collaterals in Budd-Chiari Syndrome with Tc-99m MDP Bone Scintigraphy and Tc-99m HMPAO-Labeled Leukocyte Scintigraphy
Authors: N. Ö. KÜŞÜK, ELGIN ÖZKAN, G. ARAS, K. METIN KIR
Journal: Clinical Nuclear Medicine (2003)

From Ankara University Medical Faculty, Department of Nuclear Medicine, Ankara, Turkey Received for publication June 10, 2002. Revision accepted August 26, 2002. Correspondence: Elgin Özkan, A. Ü. T. F Nükleer Tip Anabilim Dah 06100 Dikimevi-Ankara, Turkey. E-mail: [email protected]
Informed Consent and SUPPORT
Authors: Jeffrey M. Drazen, Caren G. Solomon, Michael F. Greene
Journal: New England Journal of Medicine (2013)

In the summer of 1963, the nation watched in sadness as Patrick Bouvier Kennedy, the youngest child of President John F. Kennedy and First Lady Jacqueline Bouvier Kennedy, was born prematurely and then died of lung disease 2 days later at Children's Hospital in Boston. Even now, it is common knowledge that children born prematurely are at high risk for death.So it is easy to imagine the stress when, in 2005, your new baby decides to come into the world after only 6 months of gestation, long before your pregnancy has reached term. You know that extremely premature babies . . .
Tc-99m Sestamibi Planar and SPECT Imaging of a Retrotracheal Parathyroid Adenoma
Authors: S Vidal-Sicart, F Pons, L Sabater, V Torregrosa, D Fuster, R Herranz
Journal: Clinical Nuclear Medicine (1998)

A patient with chronically increased hypercalcemia had a chest X-ray that demonstrated an enlarged mass in the upper mediastinum. Cervicothoracic CT was performed to determine the origin of this mass, but was inconclusive. The patient underwent parathyroid Tc-99m sestamibi scintigraphy which showed a large mass with increased uptake and a photopenic area inside, suggesting a parathyroid lesion. After surgery, a 30 g mass with cysts and hemorrhagic areas inside was histologically confirmed as a parathyroid adenoma.